Train harder, recover faster, perform better
One user shared their success story, reporting a 47-lb weight loss over four months, crediting the app's precise medication tracking
Despite how common GLP-1 use has become, there has been relatively little dermatology-focused research on their cutaneous side effects, with most of the existing literature limited to individual case reports. For the cross-sectional analysis, Fat and colleagues compared cutaneous adverse events reported in the FDA Adverse Event Reporting System (FAERS) for the GLP-1 receptor agonists semaglutide (Ozempic/ Wegovy, Novo Nordisk), liraglutide, exenatide and dulaglutide (Trulicity, Eli Lilly) with cutaneous adverse event reports for the dipeptidyl peptidase-4 (DPP-IV) inhibitors sitagliptin, saxagliptin, linagliptin and alogliptin
Because demand for GLP-1 medications remains high, some physicians worry the change could push patients toward unregulated or international sources
Slow titration and microdosing Some Zealthy providers recommend a slower titration schedule for patients sensitive to gastrointestinal side effects
doi: 10.1093/ajcn/81.1.122 250